# Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

> **NCT02776215** · PHASE1 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Circadian Rhythm Sleep Disorders
- Non-24 Hour Sleep-Wake Disorder
- Autism Spectrum Disorder
- Smith-Magenis Syndrome

## Interventions

- **DRUG:** tasimelteon

## Key facts

- **NCT ID:** NCT02776215
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-04
- **Primary completion:** 2017-12-20
- **Final completion:** 2017-12-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776215, "Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02776215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*